MarketCapExport financials
Larimar Therapeutics (LRMR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Larimar Therapeutics Financial Ratios 2025-2011 | LRMR
Brief overview of Larimar Therapeutics's valuation multiples
The review covers five available annual periods spanning 2015 to 2019.
The latest available valuation ratios are EV/EBITDA 0.17x (median 0.23x), P/B 4.76x (median 1.59x). Multiples are on average 86.1% above their own medians. A substantial share of positive expectations may already be priced in.
Capital efficiency is characterized by ROE -2.1%, ROA -113.6%, ROCE -2.2%. Current return ratios are negative, materially weakening the fundamental profile.
Price, earnings and growth produce a PEG of 0.48x. A value below one indicates moderate pricing relative to expected growth.
Valuation takeaway
Larimar Therapeutics's market premium is not yet supported by strong capital returns, raising valuation risk.
Annual Financial Ratios Larimar Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.2 | -3.4 | -10.3 | -4.3 | -1.5 | -3.5 | -0.2 | -0.2 | -0.2 | -0.2 | -0.2 | - | - | - | - | |
EPS |
- | -1.3 | -0.8 | -1.4 | -3.0 | -3.6 | -1.2 | -1.9 | -1.9 | -2.1 | -2.8 | -3 | -19.5 | -19.6 | - |
EV (Enterprise Value) |
354 M | 269 M | 369 M | 141 M | 19 M | 94.2 M | 10.4 M | -9.26 M | -522 K | -13.4 M | -772 K | -58.1 M | -35.5 M | -9.94 M | - |
EBITDA per Share |
-2.07 | -1.48 | -0.94 | -1.41 | -2.92 | -4.55 | -4.84 | -22.7 | -23.1 | -25.5 | -33.1 | - | - | - | - |
EV/EBITDA |
-2.1 | -3.0 | -8.9 | -3.9 | -0.3 | -2.4 | 0.2 | 0.4 | 0.1 | 0.4 | 0.2 | - | - | - | - |
PEG |
0.48 | 0.24 | 0.25 | 0.12 | 0.06 | -0.05 | -0.01 | 0.47 | -0.02 | -0.01 | 0.01 | - | - | - | - |
P/B |
4.8 | 1.6 | 4.7 | 1.4 | 1.2 | 1.6 | -15.1 | 0.1 | 0.2 | 0.1 | 0.1 | - | - | - | - |
P/CF |
-3.3 | -3.9 | -11.4 | -5.5 | -1.8 | -3.5 | -0.3 | -0.2 | -0.3 | -0.2 | -0.2 | - | - | - | - |
ROE % |
-212.17 | -46.91 | -45.21 | -31.88 | -78.61 | -47.36 | 6542.65 | -65.80 | -66.52 | -47.55 | -43.93 | - | - | - | - |
ROA % |
-113.60 | -40.26 | -38.51 | -27.97 | -64.37 | -40.58 | -56.24 | -50.40 | -49.31 | -43.97 | -39.28 | - | - | - | - |
ROCE % |
-220.91 | -52.90 | -51.10 | -32.94 | -78.35 | -44.73 | -66.61 | -56.36 | -53.96 | -47.83 | -42.77 | - | - | - | - |
Current Ratio |
2.2 | 7.0 | 6.7 | 8.2 | 5.5 | 10.9 | 5.9 | 9.1 | 14.4 | 13.2 | 11.4 | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Larimar Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | - | -0.61 | -0.41 | -0.46 | - | -0.24 | -0.34 | -0.27 | - | -0.21 | -0.19 | -0.15 | - | -0.37 | -0.47 | -0.49 | - | -0.92 | -0.79 | -0.76 | - | -0.64 | -1.21 | -1.1 | -0.19 | -1.42 | -0.61 | -0.35 | -0.39 | -0.41 | -0.57 | -0.58 | -0.48 | -0.46 | -0.49 | -0.48 | -0.38 | -0.54 | -0.55 | -0.65 | -0.85 | -0.73 | -0.66 | -0.53 | -0.48 | -0.65 | -2.96 | -6.18 | -5.35 | -4.88 | -4.37 | -4.94 | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.33 | -0.3 | - | - | -0.49 | - | - | - | -0.31 | - | - | - | -0.17 | - | -0.37 | -0.46 | -0.48 | - | -0.9 | -0.77 | -0.75 | - | -0.64 | -1.21 | -1.09 | - | -1.41 | -0.6 | -0.35 | - | -0.41 | -0.56 | -0.57 | - | -0.46 | -0.49 | -0.48 | - | -0.54 | -0.55 | -0.65 | - | -0.73 | -0.65 | -0.52 | - | -0.63 | -2.75 | -6.19 | - | -4.82 | -4.07 | - | - | - | - | - | - | - | - | - |
ROE % |
-100.63 | -95.20 | -84.27 | -60.18 | -44.69 | -24.39 | -34.17 | -34.73 | -30.64 | -24.29 | -31.30 | -38.84 | -46.13 | -39.99 | -63.31 | -74.97 | -73.00 | -57.33 | -68.79 | -58.10 | -46.87 | -31.53 | 1013.28 | 2267.97 | 2814.32 | 2812.95 | 1268.14 | 8.75 | -541.88 | -550.17 | -66.90 | -66.84 | -66.99 | -66.52 | -58.36 | -54.33 | -49.61 | -47.55 | -52.68 | -52.38 | -50.53 | -43.93 | -40.69 | -43.00 | -38.62 | -34.93 | -18.77 | 0.40 | 11.10 | 5.69 | 5.11 | 4.57 | - | - | - | - | - | - | - | - | - |
ROA % |
-76.96 | -74.33 | -67.21 | -50.86 | -39.31 | -22.10 | -30.82 | -31.23 | -27.60 | -21.70 | -27.95 | -33.02 | -38.09 | -32.60 | -51.71 | -61.04 | -60.24 | -47.69 | -57.50 | -49.21 | -40.01 | -27.01 | -166.43 | -322.50 | -382.90 | -382.38 | -254.93 | -101.41 | -43.15 | -50.40 | -50.84 | -50.39 | -50.08 | -49.31 | -44.84 | -44.06 | -42.83 | -43.97 | -48.30 | -47.66 | -45.63 | -39.28 | -36.33 | -38.31 | -34.37 | -31.04 | -31.96 | -28.65 | -31.43 | -10.22 | -9.19 | -8.22 | - | - | - | - | - | - | - | - | - |
ROCE % |
-105.45 | -100.10 | -89.61 | -65.65 | -49.71 | -28.09 | -39.24 | -39.66 | -35.22 | -27.97 | -35.14 | -41.34 | -47.28 | -40.09 | -63.31 | -74.71 | -72.72 | -57.16 | -68.68 | -58.17 | -47.04 | -31.67 | 1211.55 | 1756.80 | 1744.74 | 1752.19 | 1735.92 | 476.01 | -74.54 | -49.78 | -66.20 | -67.24 | -67.52 | -50.68 | -62.86 | -58.82 | -56.19 | -39.23 | -50.89 | -49.12 | -44.57 | -29.90 | -43.65 | -37.72 | -31.64 | -23.81 | -18.67 | -0.58 | -4.33 | - | 5.14 | 4.34 | - | - | - | - | - | - | - | - | - |
Current Ratio |
4.4 | 4.1 | 3.9 | 5.0 | 6.6 | 7.0 | 10.6 | 9.2 | 14.3 | 6.8 | 9.2 | 9.5 | 9.4 | 8.2 | 9.3 | 4.9 | 5.0 | 5.5 | 5.5 | 6.0 | 6.5 | 7.0 | 7.0 | 7.0 | 7.0 | 0.9 | 0.9 | 0.9 | 3.0 | 4.3 | 4.3 | 4.3 | 4.3 | 3.9 | 3.9 | 3.9 | 3.9 | 13.3 | 13.3 | 13.3 | 13.3 | 9.5 | 9.5 | 9.5 | 9.5 | 9.0 | 9.0 | 9.0 | 9.0 | 13.1 | 13.1 | 13.1 | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Larimar Therapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Germany
China
Israel
Australia
France
